FOLFIRI一线治疗晚期结直肠癌近期疗效观察

目的 观察FOLFIRI方案即伊立替康联合5-氟尿嘧啶(5-FU)及亚叶酸钙(LV)作为一线治疗晚期结直肠癌的近期疗效及毒性反应.方法 2007年6月至2009年7月,共32例晚期结直肠癌患者接受FOLFIRI方案化疗.FOLFIRI方案具体用法:伊立替康180 mg/m2静脉滴注90 min,第1天:LV 200 mg/m2与伊立替康同时滴入,持续时间相同,在5-FU之前,第1天和第2天;5-FU 400 mg/m2静脉推注,然后600 mg/m2持续静脉滴注22 h,第1天和第2天.14 d为1个周期.结果 32例可评价疗效患者平均治疗6个周期,总有效率为40.6%,中位缓解期7个月,无死亡病例.骨髓抑制为主要毒性反应,Ⅰ～Ⅳ度骨髓抑制发生率为71.9%;Ⅰ～Ⅱ度迟发型腹泻发生率56.2%.结论 FOLFIRI方案治疗晚期结直肠癌有效率高,毒性反应可以耐受,可作为治疗晚期结直肠癌的一线方案.Abstract：Objective To evaluate the short-term efficacy and toxicity of FOLFIRI as first-line treatment in advanced colorectal cancer. Methods From June 2007 to July 2009, 32 patients with advanced colorectal cancer received FOLFIRI chemotherapy.Regimen: irinotecan 180 mg/m2 iv drop in 90 minutes d1;LV 200 mg/m2 with irinotecan and the same time,before 5-FU,d1-2;5-FU 400 mg/m2 iv in blous, 600 mg/m2 iv drop in 22 hours, d1-2.14 day as a cycle. Results 32 cases can be appraised received 6 cycles of average therapy,the total response rate was 40.6%,the median overall survival was 7 months.The main toxic reaction was myelosuppression,Ⅰ～Ⅳ Grade myelosuppression 71.9%.Ⅰ-Ⅱ grade delayed diarrhea 56.2%. Conclusions FLOFIRI is effective for advanced colorectal cancer and the toxicreaction is tolerable.

To evaluate the short-term efficacy of FOLFIRI as first-line treatment in advanced colorectal cancer

Advanced colorectal cancer Chemotherapy Irinotecan 5-FU LV Toxic reaction